12 Month Price Forecast For CGON
Distance to CGON Price Forecasts
CGON Price Momentum
🤔 Considering CG Oncology (CGON)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 22, 2025 5:04 PM UTC
CGON Analyst Ratings & Price Targets
Based on our analysis of 8 Wall Street analysts, CGON has a consensus that is bullish. The median price target is $66.00, with forecasts ranging from $55.00 to $86.00. Currently, there are 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With CGON currently trading at $30.00, the median price forecast suggests a 120.0% upside. The most optimistic forecast comes from at , projecting a 186.7% upside, while Jeffrey Hung at Morgan Stanley provides the most conservative target, suggesting a 83.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CGON Analyst Consensus
CGON Price Target Range
Latest CGON Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CGON.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 6, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $75.00 |
| Dec 6, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $66.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $75.00 |
| Nov 12, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $75.00 |
| Oct 24, 2024 | UBS | David Dai | Buy | Initiates | $60.00 |
| Oct 8, 2024 | B of A Securities | Charlie Yang | Buy | Maintains | $65.00 |
| Sep 23, 2024 | RBC Capital | Gregory Renza | Outperform | Initiates | $66.00 |
| Sep 17, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $75.00 |
| Aug 27, 2024 | Roth MKM | Benjamin Paluch | Buy | Initiates | $65.00 |
| Jun 28, 2024 | B of A Securities | Charlie Yang | Buy | Initiates | $65.00 |
| May 28, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $75.00 |
| May 14, 2024 | Goldman Sachs | Corinne Johnson | Buy | Upgrade | $50.00 |
| May 13, 2024 | Goldman Sachs | Corinne Johnson | Buy | Upgrade | $50.00 |
| May 10, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $75.00 |
| May 6, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $75.00 |
| May 6, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $75.00 |
| May 2, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $75.00 |
| Apr 4, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $75.00 |
| Feb 20, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Initiates | $75.00 |
| Feb 20, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Initiates | $55.00 |
Stocks Similar to CG Oncology, Inc. Common stock
The following stocks are similar to CG Oncology based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CG Oncology, Inc. Common stock (CGON) Financial Data
CG Oncology, Inc. Common stock has a market capitalization of $1.95B with a P/E ratio of -1.9x. The company generates $684,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +377.8% quarter-over-quarter, while maintaining an operating margin of -65,802.3% and return on equity of -19.8%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
CG Oncology, Inc. Common stock (CGON) Company Overview
About CG Oncology, Inc. Common stock
Develops bladder cancer therapeutics.
CG Oncology, Inc. operates as a late-stage clinical biopharmaceutical company focusing on the development and commercialization of innovative therapies for bladder cancer. The company generates revenue through the clinical advancement of its product candidates, which aim to address the unmet medical needs of patients with various forms of bladder cancer, particularly those unresponsive to standard treatments.
Founded in 2010 and based in Irvine, California, CG Oncology has rebranded from Cold Genesys, Inc. to emphasize its dedicated focus on bladder cancer therapies. Its product pipeline includes multiple investigational drugs targeting high-risk bladder cancer patients, positioning the company to potentially capture significant market share in the oncology field.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
61
CEO
Mr. Arthur Kuan
Country
United States
IPO Year
2024
Website
cgoncology.comCG Oncology, Inc. Common stock (CGON) Latest News & Analysis
Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect?
6 days agoCG Oncology, Inc. (CGON) has a consensus price target indicating a 123.3% upside potential, supported by positive trends in earnings estimate revisions.
A 123.3% price target suggests significant growth potential for CG Oncology, Inc. (CGON), while rising earnings estimates indicate possible near-term stock gains.
CG Oncology, Inc. closed a public offering of 9.2 million shares at $28.00 each, with 8.5 million shares from the company and 700,000 from an existing stockholder.
CG Oncology's successful public offering raises capital for its bladder cancer therapy development, enhancing growth potential and investor confidence in its future market position.
CG Oncology Announces Pricing of Public Offering
1 month agoCG Oncology, Inc. priced a public offering of 8 million shares at $28.00 each, with 7.3 million shares from the company and 700,000 from an existing stockholder.
CG Oncology's public offering at $28 per share indicates capital raising for further development, impacting stock liquidity and investor sentiment regarding its bladder cancer therapeutic.
CG Oncology reported positive phase 3 BOND-003 results for Cretostimogene in BCG-unresponsive NMIBC. Plans to expand use in intermediate-risk patients with PIVOT-006 trial targeting 1H 2026 completion.
Positive trial results for Cretostimogene enhance CG Oncology's growth prospects, potentially boosting stock value. Expansion into new patient groups could increase market share and revenue.
CG Oncology Announces Proposed Public Offering
1 month agoCG Oncology, Inc. has filed a Form S-1 with the SEC for a proposed public offering of 7.3 million shares of common stock.
CG Oncology's public offering may dilute existing shares and impact stock price. It signals the company's need for capital, which could affect future growth and investor sentiment.
An experimental immunotherapy drug shows potential effectiveness for bladder cancer patients unresponsive to current treatments, according to recent research presented at a urology conference.
The breakthrough in immunotherapy for bladder cancer could lead to increased market share for the developing company, impacting stock prices and investment potential in the biotech sector.
Frequently Asked Questions About CGON Stock
What is CG Oncology, Inc. Common stock's (CGON) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, CG Oncology, Inc. Common stock (CGON) has a median price target of $66.00. The highest price target is $86.00 and the lowest is $55.00.
Is CGON stock a good investment in 2025?
According to current analyst ratings, CGON has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $30.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CGON stock?
Wall Street analysts predict CGON stock could reach $66.00 in the next 12 months. This represents a 120.0% increase from the current price of $30.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CG Oncology, Inc. Common stock's business model?
CG Oncology, Inc. operates as a late-stage clinical biopharmaceutical company focusing on the development and commercialization of innovative therapies for bladder cancer. The company generates revenue through the clinical advancement of its product candidates, which aim to address the unmet medical needs of patients with various forms of bladder cancer, particularly those unresponsive to standard treatments.
What is the highest forecasted price for CGON CG Oncology, Inc. Common stock?
The highest price target for CGON is $86.00 from at , which represents a 186.7% increase from the current price of $30.00.
What is the lowest forecasted price for CGON CG Oncology, Inc. Common stock?
The lowest price target for CGON is $55.00 from Jeffrey Hung at Morgan Stanley, which represents a 83.3% increase from the current price of $30.00.
What is the overall CGON consensus from analysts for CG Oncology, Inc. Common stock?
The overall analyst consensus for CGON is bullish. Out of 8 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $66.00.
How accurate are CGON stock price projections?
Stock price projections, including those for CG Oncology, Inc. Common stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
